ORMP - Oramed to Present at the Upcoming Canaccord Genuity Annual Growth Conference

PR Newswire

NEW YORK , July 11, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will present an in-person company overview and share the Company's latest updates at the Canaccord Genuity Annual Growth Conference, to be held in Boston, Massachusetts from August 8-11, 2022 .

Presentation Details:

Canaccord Genuity Annual Growth Conference

Date: Wednesday, August 10, 2022

Time: 4:30 p.m. E.T.

Location:         InterContinental Boston Hotel, 510 Atlantic Avenue, Boston, Massachusetts

The presentation will be webcasted. The link to view the presentation will be uploaded to the Oramed website ( www.oramed.com ) 48 hours before the event and will be available for 90 days following the presentation.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to transform the treatment of diabetes through its proprietary lead candidate, ORMD-0801 , which is being evaluated in two pivotal Phase 3 studies and has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule.

For more information, please visit www.oramed.com

Company Contact
Zach Herschfus
+1-844-9-ORAMED
zach@oramed.com

Logo - https://mma.prnewswire.com/media/1724339/Oramed_Logo.jpg

SOURCE Oramed Pharmaceuticals Inc.